Characteristics | Screening and Entry | Pre-treatment | Discharge | 3Â months follow-up | Annual follow-up (1 and 2Â years) | 3Â years follow-up | 10Â years follow-up |
---|---|---|---|---|---|---|---|
Diagnosis | X | Â | Â | Â | Â | Â | Â |
Written informed consent | X | Â | Â | Â | Â | Â | Â |
Past treatment history | X | Â | Â | Â | Â | Â | Â |
Demographic data | X | X | Â | Â | Â | Â | Â |
Medical history | X | X | Â | X | X | X | X |
Medication history | Â | X | X | X | X | X | X |
Physical examination | X | X | X | X | X | X | X |
Clinical neurofunctional assessment | X | X | X | X | X | X | X |
CTA scanning | X | X | X | Â | Â | Â | Â |
MRI scanning | X | X | Â | X | X | X | X |
DSA examination | X | X | Â | X | Â | X | X |
Hemodynamic evaluation | Â | X | Â | X | Â | X | X |
Treatment strategy | Â | Â | X | Â | Â | Â | Â |
Complications | Â | Â | X | X | X | X | X |
Obliteration rate | Â | Â | X | X | X | X | X |
Hemorrhagic vascular events | Â | Â | X | X | X | X | X |